SEC-FDA MOU on Information Sharing
Analysis based on 9 articles · First reported Aug 31, 2026 · Last updated Sep 07, 2026
The MOU heightens regulatory risk for life sciences companies, as inaccurate or incomplete disclosures about FDA interactions may face increased SEC enforcement. This could lead to greater compliance costs and potential volatility in biotech and pharmaceutical stocks, but also promotes market integrity and investor confidence.
On August 31, 2026, the United States — United States Securities and Exchange Commission (SEC) and the United States — Food and Drug Administration (FDA) signed a Memorandum of Understanding (MOU) establishing a formal framework for sharing non-public information about FDA-regulated products and companies. The MOU, effective immediately for three years, creates designated points of contact and standardized procedures for information requests, aiming to enhance regulatory oversight and enforcement. It allows the SEC to obtain FDA records to verify public company disclosures about clinical trials, product approvals, and FDA interactions, and enables the FDA to refer potential securities violations to the SEC. The agreement includes confidentiality safeguards, restricting redistribution of shared information without written permission. This development increases scrutiny on life sciences companies' public statements regarding FDA matters, as the SEC can now more easily cross-reference disclosures with FDA's internal records.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard